Pramomolecular

PRAMOMOLECULAR is developing drugs with a new mode of action to treat particularly aggressive forms of lung or pancreatic cancer or heart failure. In contrast to conventional therapies, it does not treat symptoms, but instead downregulates the disease-causing protein: No cancer protein - no cancer! 

PRAMO has a particularly simple enabling technology that allows gene silencing drugs to be introduced into the cells of the lungs, heart or pancreas in a particularly well-tolerated and efficient manner in the living organism. This is of great therapeutic importance, as gene silencing has so far only worked sys-temically in the liver or in local applications, e.g. in the eye. Through the combination of AI, rational drug design, automated GMP-compliant syntheses and close collaboration with a broad range of specialists worldwide, PRAMO develops drug candidates to clinical phase I/IIa in half the time and up to 1/10 of the cost of a classical pharmaceutical drug.